Busca avançada
Ano de início
Entree
Conteúdo relacionado
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Protective Cellular Immune Response Induction for Cutaneous Leishmaniasis by a New Immunochemotherapy Schedule

Texto completo
Autor(es):
da Silva, Danielle A. M. [1] ; Santana, Fabiana R. [1] ; Katz, Simone [1] ; Garcia, Daniel M. [2] ; Teixeira, Daniela [1] ; Longo-Maugeri, Ieda M. [1] ; Barbieri, Clara L. [1]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Fed Sao Paulo, Dept Microbiol Imunol & Parasitol, Escola Paulista Med, Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Dept Farmacol, Escola Paulista Med, Sao Paulo - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: FRONTIERS IN IMMUNOLOGY; v. 11, MAR 3 2020.
Citações Web of Science: 0
Resumo

The palladacycle complex DPPE 1.2 was previously shown to inhibit Leishmania (Leishmania) amazonensis infection in vitro and in vivo. The present study aimed to evaluate the effect of DPPE 1.2 associated with a recombinant cysteine proteinase, rLdccys1, and the adjuvant Propionibacterium acnes on L. (L.) amazonensis infection in two mouse strains, BALB/c, and C57BL/6. Treatment with this association potentiated the leishmanicidal effect of DPPE 1.2 resulting in a reduction of parasite load in both strains of mice which was higher compared to that found in groups treated with either DPPE 1.2 alone or associated with P. acnes or rLdccys1. The reduction of parasite load in both mice strains was followed by immunomodulation mediated by an increase of memory CD4(+) and CD8(+) T lymphocytes, IFN-gamma levels and reduction of active TGF-beta in treated animals. No infection relapse was observed 1 month after the end of treatment in mice which received DPPE 1.2 associated with rLdccys1 or rLdccys1 plus P. acnes in comparison to that exhibited by animals treated with DPPE 1.2 alone. Evaluation of serum levels of AST, ALT, urea, and creatinine showed no alterations among treated groups, indicating that this treatment schedule did not induce hepato or nephrotoxicity. These data indicate the potential use of this association as a therapeutic alternative for cutaneous leishmaniasis caused by L. (L) amazonensis. (AU)

Processo FAPESP: 17/06350-4 - Tratamento da leishmaniose visceral com Alopurinol associado à cisteína proteinase recombinante de Leishmania (Leishmania) infantum chagasi (rLdccys1).
Beneficiário:Fabiana Rodrigues de Santana
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado